Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03001479
Other study ID # 27563
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 13, 2017
Est. completion date May 1, 2023

Study information

Verified date May 2023
Source St. Louis University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Breast milk is readily accepted as the ideal source of nutrition for almost all infants, including premature or very low birth weight infants. However, these high-risk infants require the addition of fortifiers to their milk in order to achieve sufficient levels of calories, vitamins, and minerals for adequate growth. We are currently using a liquid human milk fortifier which does not provide sufficient protein intake, requiring addition of a liquid protein supplement. A new product has been released which provides sufficient protein in the liquid HMF, without the acidification seen in previous products. This is a prospective, randomized noninferiority study comparing the safety and efficacy of the new HMF with additional protein to our current standard of adding additional protein supplementation on top of the HMF.


Description:

All infants admitted to the Neonatal Intensive Care Unit (NICU) at Cardinal Glennon at gestational age <32 weeks and birthweight <1500g, and whose mothers intend to use breast milk (maternal or donor) will be approached for study participation. Infants can be enrolled at any point up until their feedings become fortified, typically around the 8th day of life. Eligible infants whose parents consent for participation will be randomized to one of the two study regimens. Sealed envelopes containing the subject treatment group will be prepared from randomization schedules that are computer-generated using a pseudorandom permuted blocks algorithm. Multiples will be randomized together to the same treatment group. The randomization will be block stratified by birth weight (500-1000g and 1001-1500g). Infants will have laboratory values to follow for signs of metabolic acidosis and nutritional status. These labs (BMP, Magnesium, Phosphorous, Alkaline Phosphatase, and prealbumin) will be drawn on study days 1, 15, and 30. Total blood volume for these labs is approximately 1.4 mL, and may be obtained by venipuncture or heel stick. These labs are monitored for nutritional sufficiency in very low birth weight infants already, the only change will be the timing that the labs are obtained. Infants will remain on their designated HMF until one of 3 different time points: 1) Infant does not tolerate HMF and must be taken off, 2) Infant is no longer receiving breastmilk and is transitioned to a premature formula, or 3) Infant is getting ready to go home and HMF is removed from the feedings. Hospitalization data will be collected on the infants until they are either discharged from the NICU or until they reach 36 weeks corrected gestational age, whichever occurs first. Data collected will include: birthweight, gestational age, gender, antenatal steroids, APGARs, days of parenteral nutrition, day enteral feedings were initiated, daily enteral volume intake, daily caloric and protein intake, day of HMF and/or liquid protein initiation. Lab data will be recorded as noted above. Growth data will be recorded by daily weights and weekly head circumferences and lengths. Intolerance will be assessed by incidence of feeding intolerance, nil per os (NPO) time, change in diet due to intolerance, incidence of metabolic acidosis, incidence of necrotizing enterocolitis, incidence of spontaneous intestinal perforation, cause of death, and length of hospital stay. Data on NICU complications, including late onset sepsis, retinopathy of prematurity, intraventricular hemorrhage, bronchopulmonary dysplasia, and use of postnatal steroids (which can affect growth) will also be recorded. Neurodevelopmental data will be collected on the infants from their first Bayley evaluation in the Nursery Follow-up clinic, usually performed at 15-18 months of age. We will record cognitive, language, and motor scores. We will also collect information on therapy services received, and incidence of blindness or deafness.


Recruitment information / eligibility

Status Completed
Enrollment 78
Est. completion date May 1, 2023
Est. primary completion date May 1, 2020
Accepts healthy volunteers No
Gender All
Age group N/A to 2 Weeks
Eligibility Inclusion Criteria: - Very low birth weight, premature infants admitted to the NICU at Cardinal Glennon - <32 weeks gestational age and birthweight <1500 grams - receiving maternal or donor breast milk Exclusion Criteria: - Infants with an estimated gestational age >32 weeks OR birthweight >1500 grams - Infants who die before fortification of feedings - Infants receiving formula - Infants that did not receive feedings with HMF - Infants transferred to another hospital prior to discharge

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid
HMF with additional hydrolyzed protein

Locations

Country Name City State
United States Cardinal Glennon Children's Medical Center Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
St. Louis University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Weight gain, short term (grams) in first 30 days on HMF 30 days
Primary Length, short term (cm) in first 30 days on HMF 30 days
Primary Head circumference, short term (cm) in first 30 days on HMF 30 days
Secondary Weight gain, long term Weight (grams) at 36 weeks corrected gestational age or time of hospital discharge, whichever is first 36 weeks gestational age or time of hospital discharge
Secondary Length, long term Length (cm) at 36 weeks corrected gestational age or time of hospital discharge, whichever is first 36 weeks gestational age or time of hospital discharge
Secondary Head circumference, long term Head circumference (cm) at 36 weeks corrected gestational age or time of hospital discharge, whichever is first 36 weeks gestational age or time of hospital discharge
Secondary feeding intolerance Signs of feeding intolerance, including loose stools, emesis, metabolic acidosis, necrotizing enterocolitis. Presence or absence of symptoms. 30 days
Secondary neurodevelopmental outcomes Bayley Scales of Infant Development III at 18 months of corrected gestational age 18 months corrected gestational age
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02452580 - The Norwegian Family Centered Care Study
Completed NCT02502916 - Enteral Feeding and Early Gut Colonization of Preterm Infants N/A
Completed NCT01748214 - Premature Infant Exposure to Noise Generated by Respiratory Support N/A
Terminated NCT02840825 - Biochip for HCMV Detection in Breast Milk
Recruiting NCT02306317 - The Adding Value of Parents to Nursing Care in the Control of FiO2 N/A
Completed NCT01354028 - Effects of Massage Therapy to Induce Sleep in Preterm Infants N/A
Completed NCT01881256 - The BabyGrow Longitudinal Study of Nutrition and Growth in Preterm Infants N/A
Completed NCT02788786 - Feasibility and Acceptability of Use of Daily Oral Rinse in Pregnant Women in Rural Nepal Phase 2
Completed NCT01678638 - Timing of Inguinal Hernia Repair in Premature Infants N/A
Recruiting NCT02623400 - The Effect of Perinatal Stress on the Development of Preterm Infants
Completed NCT02523222 - Prophylactic Dextrose Gel for Newborns at High-risk for Hypoglycemia N/A
Active, not recruiting NCT02508571 - Direct Swallowing Training and Oral Sensorimotor Stimulation in Preterm Infants N/A
Completed NCT02478684 - Delayed Cord Clamping in Preterm Neonates N/A
Completed NCT02477423 - A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome N/A
Terminated NCT02040909 - Optimizing Propofol Dosing for (Preterm) Newborn Infants That Need Endotracheal Intubation Phase 1
Completed NCT00722943 - Neuroendocrine Mechanisms of Developmental Massage Therapy (DMT) in Preterm Infants: Clinical Study N/A
Active, not recruiting NCT02832011 - How Effect Olive Oil and Eoprotin on Immunological Parameters and Growth N/A
Completed NCT02643472 - GPS (Giving Parents Support): Parent Navigation After NICU Discharge N/A
Terminated NCT01759134 - Comparison of Post-Discharge Growth of Premature Infants Using Two Different Formulas Phase 4
Completed NCT01628510 - The Developmental Effects of NICU Positioning N/A